Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Accumulated Expenses (2021 - 2025)

Abeona Therapeutics has reported Other Accumulated Expenses over the past 5 years, most recently at $2000.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $2000.0 for Q4 2025, down 96.88% from a year ago — trailing twelve months through Dec 2025 was $2000.0 (down 96.88% YoY), and the annual figure for FY2025 was $2000.0, down 96.88%.
  • Other Accumulated Expenses for Q4 2025 was $2000.0 at Abeona Therapeutics, down from $35000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for ABEO hit a ceiling of $317000.0 in Q1 2025 and a floor of $1000.0 in Q4 2023.
  • Median Other Accumulated Expenses over the past 5 years was $72000.0 (2024), compared with a mean of $115071.4.
  • Biggest five-year swings in Other Accumulated Expenses: plummeted 99.51% in 2024 and later skyrocketed 31600.0% in 2025.
  • Abeona Therapeutics' Other Accumulated Expenses stood at $296000.0 in 2021, then crashed by 31.08% to $204000.0 in 2022, then plummeted by 99.51% to $1000.0 in 2023, then soared by 6300.0% to $64000.0 in 2024, then crashed by 96.88% to $2000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $2000.0 (Q4 2025), $35000.0 (Q3 2025), and $80000.0 (Q2 2025) per Business Quant data.